Potent and highly selective antagonist for the human adenosine A3 receptor. Ki values are 2.69 nM at hA3, and > 100 μM at rat A1 and rat A2A receptors.
Sold with the permission of the NIH, US Patent 60/029,855
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 522.56. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.91 mL||9.57 mL||19.14 mL|
|5 mM||0.38 mL||1.91 mL||3.83 mL|
|10 mM||0.19 mL||0.96 mL||1.91 mL|
|50 mM||0.04 mL||0.19 mL||0.38 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Baraldi and Borea (2000) New potent and selective human adenosine A3 receptor antagonists. TiPS 21 456 PMID: 11121831
Li et al (1998) Structure-activity relationships and molecular modeling of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J.Med.Chem. 41 3186 PMID: 9703464
If you know of a relevant reference for MRS 1334, please let us know.
View Related Products by Product Action
Keywords: MRS 1334, supplier, Potent, selective, hA3, antagonists, Receptors, adenosines, MRS1334, Adenosine, A3, Receptors, Adenosine, A3, Receptors, Tocris Bioscience
6 Citations for MRS 1334
Citations are publications that use Tocris products. Selected citations for MRS 1334 include:
Lee et al (2012) Polyphenol (-)-epigallocatechin gallate-induced cardioprotection may attenuate ischemia-reperfusion injury through adenosine receptor activation: a preliminary study. EMBO Rep 63 340 PMID: 23115687
Varani et al (2011) A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther 13 R197 PMID: 22146575
Guerreiro et al (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 74 980 PMID: 18621927
Eltzschig et al (2004) Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104 3986 PMID: 15319286
Alsharif et al (2015) Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascul Pharmacol 71 201 PMID: 25869515
Corriden et al (2013) Adenosine-A3 receptors in neutrophil microdomains promote the formation of bacteria-tethering cytonemes. Nat Commun 14 726 PMID: 23817552
Do you know of a great paper that uses MRS 1334 from Tocris? If so please let us know.